Holen Sie sich die Stockscreener-App
28.92
3.47%
-1.04
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria
Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan
Arcus Biosciences awards stock options to five new employees - Stock Titan
(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com
Arcus Biosciences Announces New Employment Inducement Grants - AOL.com
Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance
RCUSArcus Biosciences Inc Latest SEC Filings - Finviz
Arcus kidney cancer drug shows 12.2-month median survival By Investing.com - Investing.com Nigeria
HIF-2a inhibition with casdatifan (IMAGE) - EurekAlert!
Arcus Biosciences (RCUS) Unveils Promising ARC-20 Study Findings on Casdatifan - GuruFocus
Arcus kidney cancer drug shows 12.2-month median survival - Investing.com
New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan - EurekAlert!
ETFs Investing in Arcus Biosciences, Inc. Stocks - TradingView
What Moves Stocks Higher? Last Week's 8 Healthcare Gainers - Forbes
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcus Biosciences Inc (RCUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
RCUS Forecast — Price Target — Prediction for 2027 - TradingView
Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS) - TradingView
Arcus Biosciences president sells $877,501 in company stock By Investing.com - Investing.com India
Form 144 Arcus Biosciences For: 24 June By Investing.com - Investing.com Nigeria
Form 4 Arcus Biosciences Inc For: 24 June By Investing.com - Investing.com South Africa
Trust sells 25,000+ RCUS Class A shares (RCUS) in two Rule 144 transactions - Stock Titan
Arcus Biosciences president sells $877,501 in company stock - Investing.com
Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing - Moomoo
Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan - Stock Titan
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus awards two new employees stock options, RSUs - Stock Titan
Arcus Biosciences stock hits 52-week high at $28.79 - Investing.com UK
Arcus Biosciences stock hits 52-week high at $28.79 By Investing.com - Investing.com Australia
Form 144 Arcus Biosciences For: 22 June By Investing.com - Investing.com Nigeria
RCUS (NYSE) plans sale of 25,000 Class A shares on 06/22/2026 - Stock Titan
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):